Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2026-05-13 AGM Information
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
EN WEB Minutes AGM 2026.pdf
AGM Information Classification · 87% confidence The document is titled “MINUTES OF THE ANNUAL GENERAL MEETING OF THE SHAREHOLDERS” and contains the detailed proceedings, attendance, agenda items and resolutions of UCB’s AGM. It is not a financial report or earnings release but the official record of the Annual General Meeting. Under our taxonomy, this best fits “AGM Information” (materials and documentation related to the AGM itself).
2026-05-13 English
FR WEB Minutes AGM 2026.pdf
AGM Information Classification · 90% confidence The document is the official “procès-verbal” (minutes) of the Annual General Meeting, detailing the opening, formalities, agenda items, and proposed resolutions of the AGM held on April 30, 2026. It is not a pre-meeting notice, nor a vote results announcement in detail, nor a full annual report or financial statements. It constitutes AGM materials/minutes and accordingly falls under AGM Information (AGM-R).
2026-05-13 French
NL WEB Minutes AGM 2026.pdf
AGM Information Classification · 91% confidence The document is the official minutes of the Annual General Meeting of Shareholders (AGM) of UCB NV held on 30 April 2026. It contains the opening, attendance verification, agenda items, and proposals submitted to shareholders. It is not an earnings release, financial report, or an announcement of report publication; it is the AGM meeting record itself. Hence, it falls under AGM Information.
2026-05-13 Dutch
EN EGM 2026 Minutes.pdf
Share Issue/Capital Change Classification · 82% confidence The document is the minutes of an extraordinary general meeting held to amend the Articles of Association, renew the authorized capital (granting the Board power to increase share capital) and to authorize the acquisition of own shares. It is not an annual report or earnings release but a corporate action notice related to share issue/capital change (and related share buyback authorization). Therefore, it best fits the “Share Issue/Capital Change” category.
2026-05-13 English
FR NL EGM 2026 Minutes.pdf
Share Issue/Capital Change Classification · 90% confidence The document is the notarial deed of an extraordinary general meeting of UCB SA held on April 30, 2026, containing resolutions to (i) renew the Board’s authorization for the company’s authorized share capital and amend Article 6 of the statutes accordingly, and (ii) renew the authorization to acquire own shares. It is not a mere announcement or link to a report but the actual act modifying the company’s articles of association, which constitutes a capital structure change. Therefore, the correct classification is Share Issue/Capital Change (SHA).
2026-05-13 French
Candid Therapeutics.pdf
M&A Activity Classification · 95% confidence The document is a detailed announcement about UCB's acquisition of Candid Therapeutics, including transaction terms, strategic rationale, and forward-looking statements. It focuses on the merger and acquisition activity, describing the deal value, assets involved, and expected closing timeline. There are no financial statements, quarterly or annual results, or regulatory filings typical of financial reports. The content aligns with an M&A announcement rather than an earnings release, annual report, or other categories. Therefore, the document fits best under the 'M&A Activity' category.
2026-05-03 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.